Featured
-
Focal Laser Ablation of Prostate Tumors With Gold Nanoparticles
How does this procedure compare with other ablative therapies for prostate cancer? Where does the research go from here? Find out what this expert had to say about a new method for treating prostate cancer. -
Radiation Therapy After Prostate Surgery Offers No Benefit
Study findings suggest that many men can be spared radiation therapy following radical prostatectomy for high-risk prostate cancer. -
Donor Kidney Use Still Suboptimal
Study reveals nearly 18% discard rate in the United States. -
FDA Approves Canagliflozin for Diabetic Kidney Disease
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients. -
Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer
First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found. -
Sipuleucel-T Efficacy, Safety in mCRPC Evaluated in Real World Study
The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months. -
Strategies to Remain in Independent Practice
Taking cash payments, working directly with employers to provide their workers with health care, and providing concierge medicine are among the approaches medical practices can take to maintain their independence. -
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations
For decades, it has been known that the mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer, but a new prospective cohort study provides the strongest evidence to date that these mutations are associated with the development of prostate cancer (PCa). The BRCA2 mutation appears… -
NAC Increases Pathologic Complete Response Rate in High-Risk MIBC
In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.
Latest Nephrology News
With Comorbidities, Less Than 6 Hours of Sleep Ups Risk for Early Death
Pioglitazone May Reduce Overall Mortality Risk in Patients With Type 2 Diabetes
eGFR Affects Risk for Opioid-Related Death, Hospitalization
Latest Urology News
Long-Term Prostate Cancer Outcomes Worse With HIFU vs RP
Brachytherapy Beneficial in Low-Risk Prostate Cancer, Study Finds
